Equities

Saniona AB

Saniona AB

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (SEK)1.85
  • Today's Change-0.036 / -1.91%
  • Shares traded320.76k
  • 1 Year change-71.79%
  • Beta0.9937
Data delayed at least 15 minutes, as of Apr 19 2024 17:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Saniona AB is a Sweden-based company active in the field of biotechnology. It operates in the area of drugs targeting ion channels to develop therapeutics for pain, central nervous system, and inflammatory or autoimmune diseases. The Company develops a technology platform which enables investigation of all types of ion channel drug targets. Its research is focused on GABAA receptors, nicotinic acetylcholine receptors and potassium channels. The clinical pipeline includes: AN788, a clinical candidate for second line treatment of major depressive disorder (MDD); AN761, to be developed for cognition deficits in schizophrenia and Alzheimer's disease; AN363, a candidate for treatment of pain disorders; and AN346, an anti-inflammatory treatment in inflammatory bowel disease (IBD); as well as several other projects. The Company is engaged in partnerships with Janssen Pharmaceuticals Inc, Pfizer Inc and Atlas Venture Inc.

  • Revenue in SEK (TTM)16.84m
  • Net income in SEK-95.81m
  • Incorporated2014
  • Employees23.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Vivesto AB0.00-128.75m170.29m14.00--0.8609-----0.2414-0.24140.000.36760.00----0.00-45.24---49.14-------------------100.00--64.80------
PMD Device Solutions AB10.21m-28.81m174.09m1.00------17.05-60.60-60.6021.39-204.840.3345--4.93---94.42-------29.08---282.27--0.0568-6.50----------------
InDex Pharmaceuticals Holding AB97.51m-95.27m175.25m7.00--0.7336--1.80-0.1766-0.17660.18250.44850.2997----13,929,290.00-29.28-37.64-33.02-41.14-82.02-450.51-97.70-454.62----0.0095----277.025.05------
Biovica International AB5.98m-122.99m178.90m37.00--1.42--29.93-2.42-2.420.1151.620.033-0.30538.43170,800.00-67.80-42.10-74.69-46.33110.09277.88-2,057.41-2,149.687.10--0.057--65.434.44-84.14---20.20--
Kancera AB0.00-64.89m181.29m3.00---------0.786-0.7860.00--------0.00---54.82---66.21-------7,249.06-------------23.64------
Circa Group AS19.60m-68.01m183.47m18.00--0.4952--9.36-0.5964-0.59640.1723.060.042--0.9809---14.56---17.56--80.17---346.99--1.99------41.82--2.46------
Active Biotech AB publ0.00-45.80m198.96m11.00--6.48-----0.1536-0.15360.000.08490.00-------96.42-57.97-126.27-97.84-------1,454.61----0.089------21.54------
Saniona AB16.84m-95.81m209.80m23.00------12.46-1.28-1.280.226-0.28950.1546--4.71732,173.90-87.96-59.16-108.11-70.15-213.08-970.05-568.94-1,483.55---3.181.44--10.19-21.0554.71---34.94--
Abliva AB137.00k-95.51m217.79m6.00--2.42--1,589.71-0.0904-0.09040.00010.0670.001--0.0034---70.40-74.59-80.95-86.98-14,491.24---69,715.33-65,958.89--------341.9493.89-12.02---19.74--
Exact Therapeutics AS0.00-35.75m223.01m8.00--4.67-----1.20-1.200.001.500.00-------49.19-33.93-57.46-38.22------------0.031------31.55------
Corline Biomedical AB25.03m-1.81m234.25m13.00--2.51--9.36-0.0841-0.08411.164.340.248--10.921,925,385.00-1.79-5.71-1.92-6.24113.38128.60-7.22-38.46---89.40----6.2874.14-177.67--62.51--
SynAct Pharma AB0.00-215.81m238.50m5.00--1.35-----6.54-6.540.004.950.00----0.00-116.46-125.17-130.53-151.70------------0.0036-------117.54------
Lipum AB (publ)0.00-37.18m244.04m----13.86-----4.05-4.050.000.47260.00-------159.35-127.85-206.31-184.50-------293,228.70----0.2781------2.38------
Thor Medical ASA0.00-5.52m247.23m1.00--0.9155-----0.0318-0.1520.001.160.00----0.00-2.52-79.17-2.84-113.94------------0.00--------------
Arctic Bioscience AS33.52m-45.20m250.68m20.00--0.9763--7.48-1.79-1.791.3310.190.10750.70252.931,687,501.00-14.50---16.61--28.96---134.86--2.53--0.0079---1.52---33.77------
Data as of Apr 19 2024. Currency figures normalised to Saniona AB's reporting currency: Swedish Krona SEK

Institutional shareholders

3.43%Per cent of shares held by top holders
HolderShares% Held
Tredje AP-fondenas of 29 Aug 20232.23m2.01%
Handelsbanken Fonder ABas of 31 Mar 2024683.73k0.62%
SEB Investment Management ABas of 28 Mar 2024419.02k0.38%
FCG Fonder ABas of 30 Jun 2022403.63k0.36%
Skandia Investment Management ABas of 29 Feb 202429.63k0.03%
Storebrand Asset Management ASas of 31 Jan 202427.33k0.03%
Case Kapitalf�rvaltning ABas of 30 Nov 202218.70k0.02%
Abante Asesores Gesti�n SGIIC SAas of 30 Jun 20230.000.00%
More ▼
Data from 31 Dec 2022 - 31 Jan 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.